Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0KA9L
|
||||
| Former ID |
DNCL002744
|
||||
| Drug Name |
AME-133v
|
||||
| Synonyms |
Ocaratuzumab
|
||||
| Drug Type |
Antibody
|
||||
| Indication | Non-hodgkin's lymphoma [ICD10:C85] | Phase 2 | [1], [2] | ||
| Company |
MENTRIK Biotech
|
||||
| Target and Pathway | |||||
| Target(s) | B-lymphocyte antigen CD20 | Target Info | [3] | ||
| KEGG Pathway | Hematopoietic cell lineage | ||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT00354926) Safety and Efficacy Study of an Anti-CD20 Monoclonal Antibody (AME-133v) to Treat Non-Hodgkin's Lymphoma. U.S. National Institutes of Health. | ||||
| REF 2 | J Clin Oncol 30, 2012 (suppl, abstr 8081). | ||||
| REF 3 | Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in FcgammaRIIIa-genotyped patients with previously treated follicular lymphoma. Clin Cancer Res. 2012 Mar 1;18(5):1395-403. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.